JP2019535645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535645A5
JP2019535645A5 JP2019513898A JP2019513898A JP2019535645A5 JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5 JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5
Authority
JP
Japan
Prior art keywords
chimeric polypeptide
cell
polypeptide according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050787 external-priority patent/WO2018049237A1/en
Publication of JP2019535645A publication Critical patent/JP2019535645A/ja
Publication of JP2019535645A5 publication Critical patent/JP2019535645A5/ja
Pending legal-status Critical Current

Links

JP2019513898A 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物 Pending JP2019535645A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662385656P 2016-09-09 2016-09-09
US62/385,656 2016-09-09
US201762553048P 2017-08-31 2017-08-31
US62/553,048 2017-08-31
PCT/US2017/050787 WO2018049237A1 (en) 2016-09-09 2017-09-08 Methods and compositions for treatment of lafora disease

Publications (2)

Publication Number Publication Date
JP2019535645A JP2019535645A (ja) 2019-12-12
JP2019535645A5 true JP2019535645A5 (enExample) 2020-10-22

Family

ID=61562328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513898A Pending JP2019535645A (ja) 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物

Country Status (7)

Country Link
US (1) US10781433B2 (enExample)
EP (1) EP3509614A4 (enExample)
JP (1) JP2019535645A (enExample)
CN (1) CN109963576A (enExample)
AU (1) AU2017322483A1 (enExample)
CA (1) CA3036524A1 (enExample)
WO (1) WO2018049237A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744840T3 (es) 2011-04-01 2020-02-26 Univ Yale Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN
WO2017218825A1 (en) 2016-06-15 2017-12-21 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
US20220305098A1 (en) * 2019-08-22 2022-09-29 The Regents Of The University Of California Ube3a for the treatment of angelman syndrome
WO2025018822A1 (ko) 2023-07-20 2025-01-23 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
KR102814185B1 (ko) 2023-07-20 2025-06-12 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011236A2 (pt) 2009-06-15 2019-07-09 4S3 Bioscience Inc métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)
WO2013155476A1 (en) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
CA2901969A1 (en) * 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
WO2014130723A1 (en) * 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
CA2936102A1 (en) * 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015192092A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
EP3186278A4 (en) * 2014-08-27 2018-04-04 Valerion Therapeutics, LLC Internalizing moieties for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2012529891A5 (enExample)
JP2011501951A5 (enExample)
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2013531470A5 (enExample)
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
JP2020511949A5 (enExample)
JP2021508449A5 (enExample)
RS55609B1 (sr) Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
EP2646472B1 (en) Covalently dimerized bivalent binding agents
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
EP2970508A2 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CN109563158A (zh) 抗补体因子bb抗体以及其用途
CN107849147A (zh) 基于二泛素突变蛋白的Her2 结合蛋白
JP7411264B2 (ja) 新規抗pad2抗体
HRP20161449T1 (hr) Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena
WO2020093789A1 (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
US20140271640A1 (en) FGF-10 Complexes
EP2928915A1 (en) Fgf-10 complexes
JP2024526356A5 (enExample)
CN102414219A (zh) 针对人ccn1的抗体及其用途
Aatsinki et al. An alternative use of basic pGEX vectors for producing both N-and C-terminal fusion proteins for production and affinity purification of antibodies
TWI857985B (zh) 胜肽之結合物及其製造方法
US20120058116A1 (en) Fgfr1c antibody combinations
JP2024501770A5 (enExample)